{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:48Z","timestamp":1789506708037,"version":"build-2803163510"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006088","name":"National Center for Emerging and Zoonotic Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128599","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:15:47Z","timestamp":1784736947000},"page":"128599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk"],"prefix":"10.1016","volume":"88","author":[{"given":"Joshua M.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker K.","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"DeSale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forrest K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy A.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Rovira-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Prutzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihid Carneiro","family":"Leao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravinda","family":"Desilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Katzelnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Salje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weiskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Paz-Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128599_bb0005","series-title":"Dengue-Global Situation","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128599_bb0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4269\/ajtmh.2012.11-0784","article-title":"Economic cost of dengue in Puerto Rico","volume":"86","author":"Halasa","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2026.128599_bb0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(23)02576-X","article-title":"Dengue","volume":"403","author":"Paz-Bailey","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128599_bb0020","series-title":"Dengue indicators","author":"Pan American Health Organization","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128599_bb0025","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0030","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1001\/jama.2024.21094","article-title":"Dengue","volume":"332","author":"Adams","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128599_bb0035","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the advisory committee on immunization practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128599_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","article-title":"Japanese encephalitis vaccine: recommendations of the advisory committee on immunization practices","volume":"68","author":"Hills","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128599_bb0045","doi-asserted-by":"crossref","first-page":"eadn2199","DOI":"10.1126\/scitranslmed.adn2199","article-title":"Primary exposure to zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1","volume":"16","author":"Zambrana","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128599_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.12688\/wellcomeopenres.15507.1","article-title":"Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines","volume":"4","author":"Flasche","year":"2019","journal-title":"Wellcome Open Research"},{"key":"10.1016\/j.vaccine.2026.128599_bb0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"New England Journal of Medicine."},{"key":"10.1016\/j.vaccine.2026.128599_bb0065","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"Dengue vaccine: WHO position paper, September 2018 - recommendations","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002181","article-title":"The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): A model comparison study","volume":"13","author":"Flasche","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110930","article-title":"Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity","volume":"39","author":"Gallichotte","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128599_bb0080","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.128599_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00440-18","article-title":"Improvement of the dengue virus (DENV) nonhuman primate model via a reverse translational approach based on dengue vaccine clinical efficacy data against DENV-2 and -4","volume":"92","author":"Barban","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0090","series-title":"Approval of Dengvaxia\u00ae (Dengue Tetravalent Vaccine, Live) for the Prevention of Dengue in Individuals Ages 9 through 16 Living in U.S. Endemic Areas","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.vaccine.2026.128599_bb0095","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.vaccine.2018.02.062","article-title":"Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines","volume":"36","author":"Vannice","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0100","doi-asserted-by":"crossref","first-page":"1081107","DOI":"10.3389\/fimmu.2022.1081107","article-title":"Recent updates on correlates of vaccine-induced protection","volume":"13","author":"Plotkin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41541-024-00872-6","article-title":"Realising the potential of correlates of protection for vaccine development, licensure and use: short summary","volume":"9","author":"King","year":"2024","journal-title":"NPJ Vaccines."},{"key":"10.1016\/j.vaccine.2026.128599_bb0110","first-page":"129","article-title":"Dengue vaccine candidates in development","volume":"338","author":"Durbin","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840104","article-title":"Current development and challenges of tetravalent live-attenuated dengue vaccines","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0120","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1080\/21645515.2018.1445448","article-title":"Safety issues from a phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine","volume":"14","author":"Halstead","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128599_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/diseases12020032","article-title":"Dengue fever epidemics and the prospect of vaccines: a systematic review and meta-analysis using clinical trials in children","volume":"12","author":"Okoye","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.vaccine.2026.128599_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7006a1","article-title":"Dengue vaccine: recommendations of the advisory committee on immunization practices, United States, 2021","volume":"70","author":"Paz-Bailey","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128599_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00593-24","article-title":"Comparison of the sensitivity and specificity of commercial anti-dengue virus IgG tests to identify persons eligible for dengue vaccination","volume":"62","author":"Medina","year":"2024","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0140","first-page":"203","article-title":"WHO position paper on dengue vaccines","volume":"99","author":"World Health Organization","year":"2024","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128599_bb0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(24)00046-1","article-title":"Brazil to start widespread dengue vaccinations","volume":"403","author":"Alves","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128599_bb0150","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/ciac690","article-title":"Safety of dengue vaccine?","volume":"76","author":"de Silva","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0155","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/s41591-025-03771-y","article-title":"Efficacy, public health impact and optimal use of the Takeda dengue vaccine","volume":"31","author":"Cracknell Daniels","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0160","article-title":"Refining uncertainty about the TAK-003 dengue vaccine with a multi-level model of clinical efficacy trial data","author":"Alkuzweny","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2026.128599_bb0165","series-title":"Takeda Announces Voluntary Withdrawal of U.S. Biologics License Application (BLA) for Dengue Vaccine Candidate TAK-003","author":"Limited TPC","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128599_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coviro.2020.09.005","article-title":"Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003\/TV005","volume":"43","author":"Durbin","year":"2020","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0175","author":"Neumam"},{"key":"10.1016\/j.vaccine.2026.128599_bb0180","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0185","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/infdis\/jix314","article-title":"Replication and excretion of the live attenuated tetravalent dengue vaccine CYD-TDV in a flavivirus-naive adult population: assessment of vaccine viremia and virus shedding","volume":"216","author":"Torresi","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0190","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.vaccine.2013.08.088","article-title":"Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA","volume":"31","author":"Dayan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0195","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0200","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1714250115","article-title":"Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials","volume":"115","author":"Juraska","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128599_bb0205","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.24196","article-title":"Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy","volume":"6","author":"Rabaa","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.vaccine.2026.128599_bb0210","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0215","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009258","article-title":"Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)","volume":"15","author":"White","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2026.128599_bb0230","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128599_bb0235","first-page":"1341","article-title":"Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil","volume":"24","author":"Nogueira","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0240","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0245","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0250","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1128\/JVI.00541-14","article-title":"Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination","volume":"88","author":"Briggs","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0255","series-title":"Federal Food, Drug, and Cosmetic Act","year":"1938"},{"key":"10.1016\/j.vaccine.2026.128599_bb0260","series-title":"Expedited programs for serious conditions\u2014drugs and biologics","author":"US Food and Drug Administration","year":"2014"},{"key":"10.1016\/j.vaccine.2026.128599_bb0265","series-title":"Accelerated Approval Program","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128599_bb0270","series-title":"When Human Efficacy Studies Are Not Ethical or Feasible. 21 CFR2002","author":"Approval of Biological Products","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128599_bb0275","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1016\/j.vaccine.2021.04.064","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico","volume":"39","author":"Arredondo","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0280","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0285","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1522136113","article-title":"Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort","volume":"113","author":"Katzelnick","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128599_bb0290","article-title":"The association of neutralizing antibodies with protection against symptomatic Dengue virus infection varies by serotype, prior infection history, and assay condition","author":"Bos","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2026.128599_bb0295","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128599_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003084","article-title":"Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity","volume":"3","author":"OhAinle","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0305","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.aac5017","article-title":"Dengue viruses cluster antigenically but not as discrete serotypes","volume":"349","author":"Katzelnick","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128599_bb0310","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk3259","article-title":"Antigenic distance between primary and secondary dengue infections correlates with disease risk","volume":"16","author":"Wang","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115366","article-title":"Distinct features of a peripheral T helper subset that drives the B cell response in dengue virus infection","volume":"44","author":"Ansari","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128599_bb0320","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128599_bb0325","doi-asserted-by":"crossref","first-page":"E4256","DOI":"10.1073\/pnas.1505956112","article-title":"Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity","volume":"112","author":"Weiskopf","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128599_bb0330","first-page":"10","article-title":"Frequency of dengue virus-specific T cells is related to infection outcome in endemic settings. JCI","author":"Galvez","year":"2025","journal-title":"Insight"},{"key":"10.1016\/j.vaccine.2026.128599_bb0335","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/JVI.02129-14","article-title":"The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes","volume":"89","author":"Weiskopf","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0340","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128599_bb0345","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0350","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41541-024-00967-0","article-title":"Long term T cell response and safety of a tetravalent dengue vaccine in healthy children","volume":"9","author":"Mandaric","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128599_bb0355","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.vaccine.2008.10.086","article-title":"Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development","volume":"27","author":"Thomas","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0360","doi-asserted-by":"crossref","first-page":"eabg9478","DOI":"10.1126\/scitranslmed.abg9478","article-title":"Dengue and zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term","volume":"13","author":"Katzelnick","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.chom.2020.12.011","article-title":"Dengue vaccines: the promise and pitfalls of antibody-mediated protection","volume":"29","author":"Martinez","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128599_bb0370","doi-asserted-by":"crossref","first-page":"eadi1734","DOI":"10.1126\/scitranslmed.adi1734","article-title":"Effects of boosting and waning in highly exposed populations on dengue epidemic dynamics","volume":"15","author":"Aogo","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128599_bb0375","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1473-3099(24)00100-2","article-title":"Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial","volume":"24","author":"Lyke","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0380","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173328","article-title":"TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies","volume":"134","author":"Pierce","year":"2024","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128599_bb0385","first-page":"1000","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine administered concomitantly or sequentially with Tdap vaccine: randomized phase IIIb trial in healthy participants 9-60 years of age in the Philippines","volume":"40","author":"Santos","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128599_bb0390","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/biostatistics\/kxac024","article-title":"A controlled effects approach to assessing immune correlates of protection","volume":"24","author":"Gilbert","year":"2023","journal-title":"Biostatistics"},{"key":"10.1016\/j.vaccine.2026.128599_bb0395","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0400","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0405","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2026.128599_bb0410","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0415","series-title":"Efficacy, public health impact and optimal use of the Takeda dengue vaccine. medRxiv. 2024:2024.08.10.24311393","author":"Daniels","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128599_bb0420","series-title":"In: Organization WH, editor. Manual for the laboratory-based surveillance of measles, rubella, and congenital rubella syndrome","article-title":"Laboratory testing for determination of population immune status","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.vaccine.2026.128599_bb0425","series-title":"Summary basis for regulatory action: PREHEVBRIO (hepatitis B vaccine, recombinant)","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128599_bb0430","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.abk0058","article-title":"Antigenic evolution of dengue viruses over 20 years","volume":"374","author":"Katzelnick","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128599_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002952","article-title":"Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development","volume":"8","author":"Salje","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005554","article-title":"Dissecting the human serum antibody response to secondary dengue virus infections","volume":"11","author":"Patel","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0445","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during world war II","volume":"1","author":"Sabin","year":"1952","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2026.128599_bb0450","article-title":"Dengue virus IgG and neutralizing antibody titers measured with standard and mature viruses are protective. Nature","volume":"16","author":"Odio","year":"2025","journal-title":"Communications"},{"key":"10.1016\/j.vaccine.2026.128599_bb0455","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J Clin Investig"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128599_bb0460","first-page":"1402","article-title":"Specificity and breadth of the neutralizing antibody response to a live-attenuated tetravalent dengue vaccine","volume":"226","author":"Demaso","year":"2022","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128599_bb0465","first-page":"1309","article-title":"Immunogenicity of a live dengue vaccine (TAK-003)","volume":"226","author":"de Silva","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0470","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41467-021-21384-0","article-title":"A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans","volume":"12","author":"Nivarthi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128599_bb0475","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, Attenuated, Tetravalent Butantan\u2013Dengue Vaccine in Children and Adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.07.014","article-title":"Multiplex sample-sparing assay for detecting type-specific antibodies to zika and dengue viruses: an assay development and validation study","volume":"6","author":"Hein","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128599_bb0485","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(24)00566-8","article-title":"Serotype-specific epidemiological patterns of inapparent versus symptomatic primary dengue virus infections: a 17-year cohort study in Nicaragua","volume":"25","author":"Bos","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0490","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128599_bb0495","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2010.01.022","article-title":"Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys","volume":"28","author":"Clements","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0500","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants","volume":"21","author":"Jodar","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128599_bb0505","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4161\/hv.28639","article-title":"Fast vaccine design and development based on correlates of protection (COPs)","volume":"10","author":"van Els","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128599_bb0510","first-page":"1","article-title":"Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices","volume":"59","author":"Rupprecht","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128599_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128599_bb0520","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128599_bb0525","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.vaccine.2026.128599_bb0530","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/infdis\/jis744","article-title":"Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated With Live Attenuated Tetravalent Dengue Vaccines","volume":"207","author":"Sun","year":"2013","journal-title":"Journal of Infectious Diseases."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600407X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600407X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:42:23Z","timestamp":1789504943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600407X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":106,"alternative-id":["S0264410X2600407X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128599","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128599"}}